Get the Stockscreener App
6.20
2.14%
0.13
After Hours:
6.20
Xeris Biopharma Holdings Inc stock is traded at $6.20, with a volume of 1.04M.
It is up +2.14% in the last 24 hours and up +13.55% over the past month.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
See More
Previous Close:
$6.07
Open:
$6.08
24h Volume:
1.04M
Relative Volume:
0.58
Market Cap:
$1.07B
Revenue:
$291.85M
Net Income/Loss:
$554.00K
P/E Ratio:
-815.79
EPS:
-0.0076
Net Cash Flow:
$27.93M
1W Performance:
+4.73%
1M Performance:
+13.55%
6M Performance:
-33.12%
1Y Performance:
+41.55%
1-Day Range:
$6.05
$6.22
1-Week Range:
$5.755
$6.22
52-Week Range:
$3.95
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.20 | 1.05B | 291.85M | 554.00K | 27.93M | -0.0076 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS) - Sahm
XERS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)? - Yahoo Finance
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
XERS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Earnings Recap: Why is Xeris Biopharma Holdings Inc stock going upWeekly Stock Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
XERS Should I Buy - Intellectia AI
XERS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2026 - BioSpace
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation - MSN
XERS Technical Analysis & Stock Price Forecast - Intellectia AI
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees - geneonline.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Tudor Investment Corp ET AL Decreases Stake in Xeris Biopharma Holdings, Inc. $XERS - marketbeat.com
Insider Sell: James Brady Sells Shares of Xeris Biopharma Holdin - GuruFocus
Brady sells Xeris Biopharma (XERS) shares worth $60,035 By Investing.com - Investing.com Australia
Brady sells Xeris Biopharma (XERS) shares worth $60,035 - Investing.com
Xeris Biopharma (XERS) director sells 10,834 shares in Rule 10b5-1 trades - Stock Titan
XERS Stock Price, Quote & Chart | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Aug Macro: Will Xeris Biopharma Holdings Inc stock recover after earningsEntry Point & AI Enhanced Trading Alerts - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard (XERS) disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares - Stock Titan
Revenue per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView
Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4%What's Next? - MarketBeat
Market Review: Can Xeris Biopharma Holdings Inc keep up with sector leaders - baoquankhu1.vn
Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility - AD HOC NEWS
Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook By Investing.com - Investing.com Canada
350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC - MarketBeat
Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise - Stock Titan
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Rosalind Advisors Inc. - MarketBeat
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com
XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - simplywall.st
XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xeris Pharmaceuticals Q2 2025 Earnings Preview - MSN
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):